• Most Popular
  • Most Shared

OXiGENE begins pivotal registration study for Zybrestat in anaplastic thyroid cancer

Mon Jul 9, 2007 2:00pm EDT
Co announces it has begun a pivotal registration study of its first-in-class vascular disrupting agent, Zybrestat (combretastatin-A4 phosphate / CA4P), in patients with metastatic anaplastic thyroid cancer.


More from Reuters

Photo

Investors seen jumping the gun on airport security

BANGALORE (Reuters) - Investors' optimism surrounding the shares of airport security systems makers could be premature as interest in the companies' products after the Christmas Day plane scare is not expected to translate into immediate orders.

» More Top News
A hiring sign hangs in a window at PETCO in Falls Church, Virginia June 5, 2009.REUTERS/Kevin Lamarque

Dust off your resumes

Employers say they'll be adding headcount in the coming year. Here's where the jobs will be.  Full Article 

ECONOMY
Tiger Woods blows on his putter on the 10th hole during final round play of the Tournament Players Championship golf tournament at the TPC at Sawgrass in Ponte Vedra, Florida May 13, 2007.

Tiger's $12 billion scandal?

Shareholders of Tiger Woods' sponsors discover that along with the upside, there are big downside risks, too, a study shows.  Full Article 

Sports